Back to discover
§ The cross-read
ABT vs DHR
ABT's Section-2 libre Market Share Loss risk is the dominant variable in any cross-read.
Fair-value ladder
Fair-value ladder unavailable — one or both tickers have no published mid fair value.
Aligned scorecards
ABTDHR
| ABTAbbott Laboratories | DHRDanaher Corporation | |
|---|---|---|
| Trend | - | - |
| Price | - | - |
| Fair value | - | - |
| FV range | - | - |
| Upside | - | - |
| Rating | Hold | Hold |
| Confidence | - | - |
| Moat | - | - |
| Archetype | - | - |
| Sector | Health Care | Health Care |
| Analyzed | - | - |
9-category scorecards
ABT
Abbott Laboratories
Valuation
1.5/10
0.11x
Management
6.4/10
0.11x
Balance Sheet
6.0/10
0.11x
Profitability
5.5/10
0.11x
Revenue Growth
6.0/10
0.11x
Risk Assessment
7.5/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
3.5/10
0.11x
Capital Efficiency
5.0/10
0.11x
Weighted Overall
5.6/10
DHR
Danaher Corporation
Valuation
4.5/10
0.11x
Management
6.9/10
0.11x
Balance Sheet
7.0/10
0.11x
Profitability
5.5/10
0.11x
Revenue Growth
4.5/10
0.11x
Risk Assessment
6.5/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
8.0/10
0.11x
Capital Efficiency
3.5/10
0.11x
Weighted Overall
6.2/10